Stock Events

Stock Events

Terns Pharmaceuticals 

$52.7
0
+$0.44+0.84% Today

Statistics

Day High
52.7
Day Low
52.7
52W High
-
52W Low
-
Volume
10
Avg. Volume
-
Mkt Cap
4.75B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q3 2025
Next
Next
-0.29
-0.29
-0.28
-0.27
Expected EPS
-0.27
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-177.71MNet Income

Analyst Ratings

$49.50Average Price Target
The highest estimate is 58.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TERN.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a leading biopharmaceutical company that competes with Terns Pharmaceuticals in the development of treatments for liver diseases, including NASH, which is a focus area for Terns.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Madrigal Pharmaceuticals focuses on the development of therapies for cardiovascular, metabolic, and liver diseases, including NASH, directly competing with Terns Pharmaceuticals' interests.
Viking Therapeutics
VKTX
Mkt Cap4.3B
Viking Therapeutics is involved in developing treatments for metabolic and endocrine disorders, including NASH, positioning it as a competitor to Terns Pharmaceuticals.
Galmed Pharmaceuticals
GLMD
Mkt Cap7.51M
Galmed Pharmaceuticals competes in the NASH treatment space, making it a direct competitor to Terns Pharmaceuticals with its focus on liver diseases.
Agios Pharmaceuticals
AGIO
Mkt Cap2.52B
Agios Pharmaceuticals, while focusing on cellular metabolism to treat diseases, has interests in liver diseases, indirectly competing with Terns Pharmaceuticals.
Enanta Pharmaceuticals
ENTA
Mkt Cap312.19M
Enanta Pharmaceuticals is focused on liver diseases and respiratory infections, making it a competitor in the liver disease space, including NASH, where Terns is active.

About

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Show more...
CEO
ISIN
US8808811074

Listings

XNAS
US
TERN
F
DE
430.F
BOATS
BOATS
TERN.BOATS

0 Comments

Share your thoughts

FAQ

What is Terns Pharmaceuticals stock price today?▼
The current price of TERN.BOATS is $52.7 USD — it has increased by +0.84% in the past 24 hours. Watch Terns Pharmaceuticals stock price performance more closely on the chart.
What is Terns Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Terns Pharmaceuticals stocks are traded under the ticker TERN.BOATS.
What is Terns Pharmaceuticals market cap?▼
Today Terns Pharmaceuticals has the market capitalization of 4.75B
When is the next Terns Pharmaceuticals earnings date?▼
Terns Pharmaceuticals is going to release the next earnings report on May 18, 2026.
What is Terns Pharmaceuticals revenue for the last year?▼
Terns Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Terns Pharmaceuticals net income for the last year?▼
TERN.BOATS net income for the last year is -177.71M USD.
When did Terns Pharmaceuticals complete a stock split?▼
Terns Pharmaceuticals has not had any recent stock splits.